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the view that mutations in genes encod-
ing g-secretase components cause
disease simply as a result of haplo-
insufficiency that leads to impaired
Notch signaling.
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TO THE EDITOR
Genetic and cellular evidence implicate
both the innate and adaptive immune
systems in the pathogenesis of cuta-
neous psoriasis (PsC) and psoriatic
arthritis (PsA), an inflammatory arthritis
that develops in approximately 30% of
PsC patients (Gladman, 2005; O’Rielly
and Rahman, 2010; Lories and de Vlam,
2012). However, little is known about
the specific pathologic differences
between PsA and PsC. Comparison of
the gene expression profiles of PsC and
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Figure 2. V75I, D185N, and P211R mutant nicastrintransactivate C-promoter binding factor-1-luciferase
reporter construct in NCSTN / cells. Transient expression of wild-type and mutant NCT in NCSTN /
cells is performed to determine whether missense nicastrin variants can rescue Notch processing and
activate endogenous C-promoter binding factor-1 to transactivate luciferase reporter construct carrying four
copies of wild-type C-promoter binding factor-1 binding sites. Luciferase reporter construct carrying four
copies of mutant C-promoter binding factor-1 binding sites is used as a specificity control. The data
represent the mean±SEM (n¼ 3). ***Indicates a significant difference from the vector control (Po0.005).
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PsA patients can provide valuable insight
into such differences and concurrently
identify candidate biomarkers of PsA.
We compared PAXgene whole blood
gene expression between patients with
active PsA (n¼20), PsC (n¼ 20), and
healthy controls (n¼12) using Agilent
44k Human Oligo microarrays (Agilent
Technologies, Mississauga, ON,
Canada). The study was approved by
the University Health Network Research
Ethics Board, and all subjects provided
written informed consent. In brief, PsA
and PsC patients were matched for
psoriasis area severity index and psor-
iasis duration, and controls were
matched for age, sex, and ethnicity.
Differential expression was assessed by
linear regression adjusting for factors
that significantly affected gene expres-
sion, such as batch effects, sex, psoriasis
duration, and age of psoriasis onset
(Supplementary Materials online).
At a false discovery rate adjusted
qo0.05, 1,125 genes were differentially
expressed between PsA patients and
healthy controls (56% upregulated and
44% downregulated), and 494 genes
were differentially expressed between
PsA and PsC patients (24% upregulated
and 76% downregulated). Surprisingly,
there were no differentially expressed
genes between PsC patients and con-
trols. We speculated that this was due to
a weak whole blood signature of cuta-
neous disease that was ‘‘drowned out’’
by the cellular heterogeneity of whole
blood. However, many of the differen-
tially expressed genes between PsA and
PsC patients changed with smaller mag-
nitude in PsC patients compared with
controls (Figure 1), suggesting that the
more severe phenotype of PsA is an
exacerbation of small gene expression
changes that occur in PsC.
Genes upregulated in PsA compared
with PsC were enriched in the biologi-
cal annotations anchored to membrane,
cell proliferation, cytokine activity, ribo-
nucleoprotein, and tumor necrosis fac-
tor, whereas genes downregulated in
PsA were enriched in the terms chro-
matin modification, nuclear lumen,
RNA splicing, and DNA/RNA helicase
activity (Supplementary Table S1
online). The top hits were involved in
processes such as Toll-like receptor
signaling (LY96, ABCA1, TICAM1),
NK cell activation (CD58, CLEC2B),
gene expression regulation by NF-kB
(BCL2A1), osteoclastogenesis (TGFBR3,
NOTCH2NL), epidermal development
(CSTA), cell–cell recognition, signaling,
and movement (MSN, EZR), and
chromatin modification (SETD2,
SMARCA4) (Supplementary Table S2
online).
Toll-like receptor signaling pathways
activate the master transcription
factor NF-kB, which translocates to the
nucleus and induces expression of
numerous inflammatory genes (Kawai
and Akira, 2007). Recruitment of
NF-kB and induction of its targets
involve chromatin modification and
remodeling complexes (Natoli, 2009;
Lawrence and Natoli, 2011). Because
these pathways were overrepresented
on the microarray, we examined them
in greater detail using targeted quanti-
tative PCR arrays and identified several
additional differentially expressed genes
between PsA and PsC patients (qo0.05),
including TBK1 and HAT1 (upregulated),
and G9A, IKBKB, NF-kB1 (p50), c-Rel
(Rel), and RelA (p65) (downregulated)
(Supplementary Table S3, Supplemen-
tary Materials online). CXCL10 (upregu-
lated) was also differentially expressed
before correction for multiple testing
(Po0.05). These results suggest that
innate immunity may be important in
the pathogenesis of PsA in PsC patients,
particularly through Toll-like receptor
signaling, NF-kB, and downstream chro-
matin remodeling events.
Delayed diagnosis and treatment of
PsA can result in joint damage and
disability (Gladman et al., 2011;
Haroon et al., 2014). Diagnosis could
be expedited by the availability of
biomarkers of PsA in PsC patients.
Candidate PsA biomarkers showed
high concordance to array results
when validated in the same samples
by both gold-standard quantitative PCR
and nCounter technology (Geiss et al.,
2008) (r¼0.98, Po0.001 and r¼ 0.96,
Po0.001, respectively) (Supplementary
Materials online). However, in a small
number of cases fold changes of 40.9
and o1.2 were discordant between
the arrays and nCounter. Accordingly,
genes with larger fold changes of 41.5
or o0.67 were prioritized for further
nCounter testing in an independent
replication cohort of consecutive PsA
and PsC patients not receiving biologic
treatment (48 each) (Table 1).
Thirteen genes were significant in the
replication cohort (qo0.05), of which
four genes (NOTCH2NL, CXCL10,
1.5
1.0
0.5
0.0
–1.0
Lo
g 
FC
 (P
sA
 ve
rsu
s P
sC
)
–2.0
–1.0 –0.5
Log FC (PsC versus controls)
0.0 0.5 1.0 1.5 2.0
Figure 1. Relationship between the skin and joint disease based on gene expression. Scatter plot of each
differentially expressed gene found in PsA versus controls, using the log fold change (FC) values from psoriatic
arthritis (PsA) versus cutaneous psoriasis without arthritis (PsC) (joint disease signature) plotted against PsC
versus controls (skin disease signature). The majority of genes fall within the first and third quadrants,
indicating that genes increased or decreased in PsA relative to PsC are changed in the same direction in PsC
relative to controls. Fold changes in PsA versus PsC were typically larger in magnitude compared with fold
changes in PsC versus controls, as evidenced by where fold changes fall relative to the diagonal line.
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HAT1, and SETD2) had fold changes
concordant with the discovery cohort
(Table 1). NOTCH2NL, a homolog of
NOTCH2, which is activated by RANKL
and promotes the development of osteo-
clasts from bone marrow macrophages
(Duan et al., 2004; Fukushima et al.,
2008), was the strongest biomarker of
PsA with the highest receiver operating
characteristics area under the curve
(AUC¼0.71). As a combined panel of
4 genes (calculated as previously
described in Chandran et al. (2010)),
the AUC increased synergistically to
0.79. NOTCH2NL expression was posi-
tively correlated with swollen joint count
(r¼0.46, P¼0.02), and SETD2 expres-
sion was negatively correlated with ESR
(r¼ 0.59, P¼0.003) independent of
sex, age, and psoriasis duration.
Several other genes were highly sig-
nificant in the replication cohort but
showed an opposite direction of fold
change compared with the discovery
cohort (Table 1). We speculated that
this was due to subtle demographic or
clinical differences between the two
cohorts. Indeed, the discovery PsA
cohort was characterized by a signifi-
cantly younger age of PsA onset, longer
PsA duration, and higher swollen joint
count compared with the replication
PsA cohort (Po0.05). Differences in
PsC duration, swollen and/or tender
joint count, lymphocyte count, and non-
steroidal anti-inflammatory drug or dis-
ease-modifying antirheumatic drug use
nearly reached significance (Po0.10,
Supplementary Table S4 online). No
differences were found between the
PsC cohorts. With the exception of age
of PsA onset and lymphocyte count,
these clinical variables were correlated
with the expression of SYNCRIP,
CD58, LY96, EZR, MSN, and P2RY5
(Supplementary Table S5 online), which
might explain why these genes showed
opposing fold changes in the two
cohorts. Given their strong differential
expression, these genes should not be
precluded from further study. However,
careful attention must be paid to clinical
variables when selecting PsC and PsA
patients for testing.
In conclusion, whole blood gene
expression profiling suggests that innate
immunity may be important in the
pathogenesis of PsA, via Toll-like recep-
tor signaling, NF-kB, and various chro-
matin remodeling complexes. This
finding is consistent with evidence
implicating environmental triggers of
the innate immune system, such as
infections or tissue damage (called the
‘‘deep’’ Kobner phenomenon) in the
development of PsA in PsC patients
(Chandran and Raychaudhuri, 2010;
Eder et al., 2011). Gene expression
profiling also identified potential
Table 1. Candidate genes selected for replication testing in an independent cohort by nCounter technology
Gene symbol Gene name (alias)
Arrays1 nCounter2
AUC (95% CI)
Fold change
PsA versus PsC q value
Fold change
PsA versus PsC q value
NOTCH2NL NOTCH2 N-terminal like (N2N) 0.55 0.01 0.80 o0.001 0.71 (0.61–0.82)
HAT1 Histone acetyltransferase 1 (KAT1) 1.77 0.001 1.12 0.02 0.68 (0.58–0.79)
SETD2 SET domain containing 2 (HIF-1) 0.62 0.04 0.92 0.03 0.63 (0.52–0.74)
CXCL10 Chemokine (C-X-C motif) ligand 10 (IP-10) 1.53 0.23 1.45 0.04 0.65 (0.53–0.76)
CD58 Cluster of differentiation 58 (LFA-3) 1.57 0.04 0.77 o0.001 0.78 (0.68–0.87)
LY96 Lymphocyte antigen 96 (MD-2) 2.23 0.02 0.69 o0.001 0.78 (0.68–0.89)
G9A Euchromatic histone-lysine
N-methyltransferase 2 (EHMT2/BAT8)
0.64 o0.001 1.31 o0.001 0.74 (0.64–0.84)
BCL2A1 BCL2-related protein A1 (ACC-1) 2.28 0.03 0.73 o0.001 0.78 (0.68–0.87)
SYNCRIP Synaptotagmin binding, cytoplasmic
RNA interacting protein (HNRNPQ)
0.67 0.02 1.34 o0.001 0.75 (0.65–0.87)
CLEC2B C-type lectin domain family 2, member B (AICL) 2.56 0.02 0.79 0.003 0.79 (0.69–0.88)
PRMT6 Protein arginine methyltransferase 6 (HRMT1L6) 0.64 0.12 1.24 0.01 0.68 (0.58–0.79)
EZR Ezrin (VIL2) 0.63 0.003 1.35 0.02 0.74 (0.64–0.85)
MSN Moesin (HEL70) 0.60 0.01 1.16 0.02 0.77 (0.67–0.87)
P2RY5 Lysophosphatidic acid receptor 6 (LPAR6) 2.27 0.02 1.09 0.07 0.60 (0.40–0.64)
TGFBR3 Transforming growth factor beta receptor 3 (betaglycan) 0.47 0.02 1.22 0.09 0.64 (0.53–0.75)
TNFSF10 Tumor necrosis factor (ligand) superfamily,
member 10 (TRAIL)
1.53 0.02 0.95 0.21 0.56 (0.44–0.67)
CLEC4D C-type lectin domain family 4, member D (CLEC-6) 2.43 0.03 1.01 0.25 0.48 (0.37–0.60)
CSTA Cystatin/stefin A (STFA) 2.55 0.02 1.01 0.27 0.52 (0.40–0.64)
Abbreviations: PsA, psoriatic arthritis; PsC, cutaneous psoriasis without arthritis.
1Discovery cohort (microarray analysis of 20 PsA, 20 PsC patients, and 12 controls, or quantitative PCR array analysis of the same 19 PsA and 18 PsC patients).
2Validation cohort (nCounter analysis of 48 PsA and 48 PsC patients).
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biomarkers of PsA in PsC patients, most
notably NOTCH2NL, HAT1, CXCL10,
and SETD2, which were associated with
PsA irrespective of clinical differences
between patients. Because of the small
sample size and limited power of the
present study, further validation of these
preliminary findings at the RNA and
protein levels in larger cohorts of PsA
and PsC patients is necessary.
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TO THE EDITOR
Dermatitis herpetiformis (DH), a cuta-
neous manifestation of celiac disease, is
characterized by the deposition of gran-
ular IgA in dermal papillary tips. It has
been shown that transglutaminase 3
(TG3) colocalizes with the IgA in dermal
papillae (Sardy et al., 2002). However,
the additional roles that TG3 may have in
the pathogenesis of DH remain unclear.
Transglutaminase is a family of
enzymes that catalyze posttranslational
modification reactions by transami-
dation, esterification, and hydrolysis
(Iismaa et al., 2009). In celiac disease,
transglutaminase 2 (TG2) has been found
to be crucial in the pathogenesis by
deamidating gliadin and in the
formation of antigenic gliadin-TG2
complexes.
Fibrin (Mustakallio et al., 1970) and
fibronectin (Reitamo et al., 1981) have
been shown to bind in a pattern similar
to IgA in the initial lesions of DH. In our
study of the deposits localized in the
dermal papillae of DH skin, we noted
not only similar localization of fibri-
nogen deposits with the IgA-TG3 com-
plexes but that the stain intensity pattern
of these deposits indicated a similar
quantitative pattern as well. On exami-
nation of biopsies from 13 patients with
DH, photographic overlays of cryosec-
tioned skin stained by direct immuno-
fluorescence for IgA and fibrinogenAccepted article preview online 1 September 2014; published online 25 September 2014
Abbreviations: DH, dermatitis herpetiformis; LABD, linear IgA bullous dermatosis; TG2, transglutaminase 2;
TG3, transglutaminase 3; uPA, urokinase-type plasminogen activator
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